Holen Sie sich die Stockscreener-App
4.385
0.10%
-0.025
Schlusskurs vom Vortag:
$4.41
Offen:
$4.47
24-Stunden-Volumen:
890.13K
Relative Volume:
0.31
Marktkapitalisierung:
$555.04M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-110.78M
KGV:
-5.0402
EPS:
-0.87
Netto-Cashflow:
$-75.59M
1W Leistung:
-8.98%
1M Leistung:
-17.50%
6M Leistung:
-37.33%
1J Leistung:
+80.55%
1-Tages-Spanne:
$4.365
$4.63
1-Wochen-Bereich:
$4.15
$5.025
52-Wochen-Spanne:
$2.43
$9.97
Humacyte Inc Stock (HUMA) Company Profile
Firmenname
Humacyte Inc
Sektor
Branche
Telefon
919-313-9633
Adresse
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Vergleichen Sie HUMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| HUMA | 4.385 | 555.04M | 0 | -110.78M | -75.59M | -0.87 |
| VRTX | 446.48 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 740.49 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.15 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.56 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.47 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-14 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-16 | Herabstufung | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | Eingeleitet | Cowen | Outperform |
| 2021-09-24 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-22 | Eingeleitet | BTIG Research | Buy |
| 2021-09-16 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Humacyte Inc Aktie (HUMA) Neueste Nachrichten
HUMA INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $00,000 In HUMA To Contact Him Directly To Discuss Their Options - PR Newswire
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery - The Manila Times
Humacyte director Brady Dougan buys $7,978 in common stock - Investing.com
Humacyte CEO Laura Niklason buys shares worth $7,978 - Investing.com
Humacyte director Brady Dougan sells shares worth $6.6 million - Investing.com
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit - The Malaysian Reserve
Humacyte CEO Laura Niklason sells $6.6m in common stock - Investing.com
HUMA LAWSUIT ALERT: Levi & Korsinsky LLP Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - TipRanks
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Investors - Business Wire
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Blood Vessel Maker Faces Investor Suit Over FDA Findings - Law360
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Humacyte, Inc. - PR Newswire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Investors - Business Wire
Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights - The Bakersfield Californian
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Shareholder lawsuit shines light on biotech's FDA woes - The Business Journals
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Humacyte (HUMA) Faces Class Action Lawsuit After FDA Inspection Reveals Manufacturing Issues– Hagens Berman - GlobeNewswire
HUMA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Humacyte, Inc. - Business Wire
Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association's Scientific Sessions 2024 - The Manila Times
Humacyte, Inc. Presents Preclinical Results of Small-Diameter ATEV?? for Coronary Artery Bypass Grafting at American Heart Association's Scientific Sessions 2024 - Marketscreener.com
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman - GlobeNewswire
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman - GlobeNewswire Inc.
Humacyte, Inc. (HUMA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
HC Wainwright Decreases Earnings Estimates for Humacyte - MarketBeat
Humacyte Advances with $15M Direct Offering - TipRanks
Cantor Fitzgerald Reduces Earnings Estimates for Humacyte - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Humacyte, Inc. (HUMA) Shareholders to Inquire about Securities Investigation - AccessWire
Humacyte Announces Pricing of $15.0 Million Registered Direct Offering - The Manila Times
Humacyte's (HUMA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Humacyte, Inc. (HUMA) And Encourages Shareholders to Reach Out - AccessWire
Humacyte (HUMA) Faces Questions After FDA Inspection – Hagens Berman - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Humacyte, Inc. (HUMA) Stockholders to Inquire about Securities Investigation - AccessWire
Humacyte, Inc. (NASDAQ:HUMA) Q3 2024 Earnings Call Transcript - Insider Monkey
Humacyte Q3 2024 Earnings Preview - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humacyte, Inc.HUMA - cnhinews.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Humacyte, Inc. (HUMA) and Encourages Investors to Learn More About the Investigation - AccessWire
Humacyte (NASDAQ:HUMA) Shares Up 11%Time to Buy? - MarketBeat
Humacyte Reports Q3 2024 Results Amid FDA Review - TipRanks
Humacyte Inc (HUMA) Quarterly 10-Q Report - Quartz
Humacyte Third Quarter 2024 Financial Results and Business Update - WICZ
Objective long/short (HUMA) Report - Stock Traders Daily
Humacyte, Inc. (HUMA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Research Analysts Offer Predictions for Humacyte Q3 Earnings - MarketBeat
Humacyte (HUMA) to Release Quarterly Earnings on Friday - MarketBeat
The Law Offices of Frank R. Cruz Continues Its Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors - Business Wire
Analysts Issue Forecasts for Humacyte FY2028 Earnings - MarketBeat
Finanzdaten der Humacyte Inc-Aktie (HUMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):